Rising THC concentrations in commercial cannabis products pose escalating risks for motor vehicle safety as legalization expands across jurisdictions. This controlled research provides the first systematic evidence that driving impairment increases proportionally with cannabis potency, challenging assumptions that experienced users develop tolerance to functional deficits.
The crossover trial exposed regular cannabis users to four conditions: placebo and three THC concentrations (6.25%, 12.5%, and 22%). While average driving speed remained consistent across all conditions, key safety metrics deteriorated progressively with higher potency. Participants showed increased maximum speeds and longer reaction times at medium and high concentrations, with lateral position control suffering across all THC levels. Blood THC measurements confirmed dose-dependent relationships between cannabinoid exposure and performance decrements.
These findings carry significant implications for cannabis policy and personal safety decisions. Unlike alcohol, where impairment thresholds are well-established, THC's effects on driving have remained poorly quantified despite widespread legalization. The research demonstrates that even experienced users cannot compensate for higher potency products through behavioral adaptation. Modern dispensary products often exceed the study's highest concentration, suggesting real-world impairment may be even more pronounced. The results also validate participants' self-assessments of reduced driving capability, indicating preserved insight despite intoxication. However, the simulator environment may not capture all complexities of actual road conditions, and the study's focus on regular users limits generalizability to occasional consumers who may show greater sensitivity to THC's impairing effects.